Development of magnetic resonance methods for functional imaging of the skeletal muscle
Dr. Francesco Santini, Division of Radiological Physics, University Hospital Basel
Abstract (Lay summary see below)
Assessing the functionality of skeletal muscle fibers is essential in the monitoring of progress of both pathological (neuro- and musculodegenerative) and physiological processes (training and rehabilitation). Although morphological information is of utmost importance and primarily used in longitudinal followup of a single patient, it is not an absolute marker of organ health. In order to obtain an absolute indication of muscle status, it is necessary to follow a functional approach, which should monitor the ability of the muscle itself to contract and gather supply of nutrients and oxygen from the blood.
In this project, we intend to develop new procedures for the imaging of muscle functionality that rely on the usage of Electrical Muscle Stimulation (EMS) during Magnetic Resonance Imaging (MRI). EMS can non-invasively induce contraction of the skeletal muscles through an electrical pulse that can be controlled in shape, intensity and duration. This allows for standardization of the displacement and level of exercise by means of quantitative parameters such as duration and frequency of contractions and current/phase charge delivered to the organ.
Our planned investigation consists of two interconnecting lines of development: on the one hand, we will develop and refine a device that synchronizes the stimulation with the image acquisition, and on the other hand, we will adapt various acquisition methodologies (velocity and oxygenation/perfusion imaging) to work in combination of the stimulation. In order to achieve accurate dynamic and functional imaging of the skeletal muscles, it is important to obtain a good (ideally sub-millisecond) synchronization between the MR acquisition and the contraction.
Our preliminary work using a trigger circuit connected at the output of a clinical EMS device and activated by the optical synchronization signal sent by the MR scanner showed very promising results in this direction. In this project, we will refine the design of the trigger circuit allowing higher control over the stimulation waveform modulation. With our proposed approach high-temporal-resolution dynamic MR imaging can be performed. Existing methods are commonly used for cardiac imaging and need to be adapted and optimized in order to image movements happening roughly 10 times faster (within 100-200ms) than the average cardiac cycle (1000ms).
Another important parameter for the assessment of muscle functionality is its metabolic response. In the frame of this project, we intend to exploit the reproducibility of muscle contractions generated by the EMS to measure oxygenation/muscle fiber activation during constant exercise. In order to achieve this goal, existing T2-, T2*- and perfusion-weighted acquisition sequences will need to be adapted to be synchronized with the stimulus. The method will be tested on healthy volunteers and a study of the muscle characteristics in multiple age groups will be performed to assess the sensitivity of the methodology to aging.
Lay summary
Sviluppo di metodi di risonanza magnetica per l'imaging funzionale dei muscoli scheletrici
La misurazione della funzionalità delle fibre dei muscoli scheletrici è essenziale per valutare l'avanzamento di processi sia patologici (patologie degenerative dei muscoli o neurali), sia fisiologici (allenamento e riabilitazione in seguito a infortuni).
Nonostante il semplice imaging morfologico fornisca già informazioni essenziali, che fanno sì che venga già utilizzato per monitorare la progressione di una malattia sul singolo paziente, non è un indicatore assoluto dello stato di salute dell'organo. Per poter ottenere una valutazione oggettiva e assoluta, è necessario seguire un approccio funzionale, che dia informazioni sulla capacità del muscolo stesso di contrarsi e di assorbire nutrimento e ossigeno dal sangue per la funzionalità del suo metabolismo.
In questo progetto, vogliamo sviluppare delle nuove procedure per l'imaging della funzionalità muscolare che utilizzano l'elettrostimolazione del muscolo durante l'imaging a risonanza magnetica (MRI). L'elettrostimolazione può, in modo non invasivo, indurre la contrazione dei muscoli in maniera controllata e riproducibile.
Intendiamo utilizzare questo metodo per ottenere immagini dinamiche del muscolo con una risoluzione temporale di pochi millisecondi, in modo da visualizzare la dinamica della contrazione muscolare. Questo approccio è simile all'imaging cardiaco, in cui la contrazione avviene naturalmente in modo periodico e riproducibile.
Un altro aspetto che considereremo sarà l'imaging metabolico. Utilizzeremo la riproducibilità dell'esercizio muscolare indotto dall'elettrostimolatore per monitorare nel tempo l'ossigenazione del muscolo tramite l'adattamento di metodi esistenti per l'analisi della perfusione.
La futura applicazione di questi metodi sarà potenzialmente sia nella ricerca preclinica sia nella ricerca clinica, per la valutazione di patologie degenerative (ad esempio malattie neurodegenerative e distrofie). Un altra applicazione possibile di questi metodi sarà la valutazione della riabilitazione dopo un trauma osseo o muscolare, anche applicato alla medicina dello sport.
Projets
- Nouveaux projets de recherche dès 2024
- L'importance de la recherche
- Projets financés
- Unstructured proteins as therapeutic targets for neuromuscular diseases
- Open and reproducible pipeline for the acquisition and analysis of muscle MRI data in Facioscapulohumeral Muscular Dystrophy
- Dissecting lysosomal signals to fight Pompe disease
- Functional properties and epigenetic signature of quiescent and early activated human muscle reserve cells
- Activation of human skeletal muscle stem cells:role of Orai3 ans its partner AHNAK2 in physiological condition and in Duchenne Muscular Dystrophy
- Understanding the clinical spectrum associated with VMA21 deficiency
- ANTXR2 as a key player in Collagen VI signaling in muscle stem cells: new therapeutic perspectives for COL6-related myopathies.
- Molecular mechanisms of complement activation and neuromuscular disruption by combinations of autoantibodies from patients with Myasthenia Gravis
- From the investigation of the role of SRSF1 in ALS/FTD to its targeting as a therapeutic strategy
- Molecular crosstalk between muscles and motor neurons and its role in neuromuscular circuit formation
- Molecular Diagnosis and Coping Mechanisms in Mitochondrial Myopathies
- IPRIMYO: Immune-privileged, immortal, myogenic stem cells for gene therapy of Muscular Dystrophy
- Effect of RYR1 mutations on muscle spindle function and their impact on the musculoskeletal system
- Therapeutic potential of human myogenic reserve cells in Duchenne Muscular Dystrophy
- Glutamine metabolism as a potential target for Duchenne Muscular Dystrophy
- Targeting protein s-acylation during Tubular Aggregate Myopathy
- Aggravating the phenotype of dystrophic mice for improving preclinical research and clinical translation for Duchenne muscular dystrophy
- Characterization of autoreactive T cells in Guillain-Barré syndrome
- A vascularized human muscle-on-a-chip to elucidate the contribution of endothelial-mesenchymal transition on the progression of muscular dystrophies
- Characterization of a novel form of ALS associated with changes in the sphingolipid metabolism
- Pre-clinical treatment of mouse models carrying recessive Ryr1 mutations with HDAC/DNA methyltransferase inhibitors.
- New aspects of TGFβ signaling in muscle homeostasis and regeneration
- Inhibition of sphingolipid synthesis as a treatment strategy for Duchenne muscular dystrophy
- Tamoxifen in Duchenne muscular dystrophy (TAMDMD)
- DNA aptamers against the DUX4 protein reveal novel therapeutic implications for FSHD
- Facilitating diagnosis of critical illness myopathy using muscle excitability testing
- Rapid Exploratory Imaging for High-resolution and Whole Extremity Coverage in MR Neurography
- Deciphering novel mechanisms and effectors contributing to muscle dysfunction in Myotonic Dystrophy Type I
- Can HDAC/DNA methyltransferase inhibitors improve muscle function in a congenital myopathy caused by recessive RYR1 mutations?
- Identification of the critical regulators of protein synthesis and degradation in human muscle atrophy
- Exploring peripheral B-cell-helper T cell phenotypes in the blood of patients with Myasthenia gravis using mass cytometry (CyTOF)
- Molecular signature, metabolic profile and therapeutic potential of human myogenic reserve cells
- A multicenter cross-sectional and longitudinal study of the Swiss cohort of Merosin-negative congenital muscular dystrophy
- Targeting NADPH oxidase 4 in models of Duchenne muscular dystrophy
- Characterizing the role of ER stress in C9orf72-linked ALS pathology
- Inducing mitophagy with Urolithin A to restore mitochondrial and muscle function in muscular dystrophy
- Motor unit action potentials analysis in patients with myopathies with a new wireless portable and multichannel Surface EMG device (WPM-SEMG)
- Role and therapeutic potential of PLIN3 in neuromuscular diseases
- Changes in ventilation distribution in children with neuromuscular disease using the insufflator/exsufflator technique: An observational study
- Mechanism and function of genome organization in muscle development and integrity
- Role and therapeutic potential of NADPH oxidases in a mouse model of Duchenne Muscular Dystrophy
- Characterization of pathological pathways activated in muscles of patients with congenital myopathies with disturbed Ca2+ homeostasis
- Creation of a study team to conduct an SMA 1-clinical trial at the Centre for Neuromuscular Diseases of the University Children's Hospital Basel (UKBB)
- Novel treatment to stop progressive neuropathy and muscle weakness in multifocal motor neuropathy
- Understanding the pathomechanisms leading to muscle alterations in Myotonic Dystrophy type I
- Automated volumetry and quantitative MRI to diagnose peripheral nerve lesions – translational proposal for a new clinical diagnostic imaging tool
- Novel approaches against Spinal Muscular Atrophy by targeting splicing regulators
- Protective effects and mechanisms of action of tamoxifen in mice with severe muscular diseases
- Role of the receptor FgfrL1 in the development of slow muscle fibers
- Muscle velocity recovery cycles: A new tool for early diagnosis of critical illness myopathy
- Generation of uncommitted human IPSC derived muscle stem cells for therapeutic applications
- Transposable vectors for dystrophin-expression in a murine model for muscular dystrophy
- Cardiac involvement in patients with Duchenne/Becker Muscular Dystrophy; an observational study
- Deciphering the pathogenic mechanisms of C9ORF72 ALS
- Enhancing estrogenic signalling to fight muscular dystrophies: Mechanisms of action and repurposing clinically approved drugs
- Mechanisms and therapeutic potential of modulating PGC‐1α to alter neuromuscular junction morphology and function
- Triggering human myoblast differentiation: from EGFR to myogenic transcription factors
- Improving cellular therapies of muscle dystrophies by uncovering epigenetic and signaling pathways of muscle formation
- Protein engineering in an attempt to increase the mechanical, integrin dependent cytoskeleton-matrix linkage in muscle fibers
- Muscle velocity recovery cycles: a new tool for characterization of muscle disease in vivo
- Excessive neurotrypsin activation and agrin cleavage-a pathogenic condition leading to sarcopenia-like muscle atrophy?
- Evaluation of novel treatment strategies for dyspherlinopathies in mouse models
- Cell therapy of LGMD2D by donor HLA-characterized human mesoangioblasts (hMABs) produced in GMP conditions
- In search of small molecules targeting protein-RNA complex: a novel approach against Spinal Muscular Atrophy
- Restoration of autophagy as a new strategy for the treatment of congenital muscular dystrophies
- Development of magnetic resonance methods for functional imaging of the skeletal muscle
- Targeting ER stress response: a potential mechanism for neuroprotection in Amyotrophic Lateral Sclerosis
- Generation of uncommitted human IPSC derived muscle stem cells for therapeutic applications
- Brochure décrivant les projets
- SEAL Therapeutics AG
- Rencontres et séminaires
- Participation à des associations faîtières
- Les registres de patients
- Le réseau Myosuisse
FSRMM
- Chemin des Saules 4B
2013 Colombier - +41 78 629 63 92
- philippe.rognon@fsrmm.ch